ALK Tyrosine Kinase Inhibitor (class)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ALK Tyrosine Kinase Inhibitor (class), covering 2024-09-20 to 2024-09-20. Get the full timeline:
Most recent: Clinical Trial Update: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma [Phase 2]